Back to mobile site

Raymond James Reiterates Outperform Rating on Legend Biotech Corp. (LEGN) following Q4

March 10, 2026 3:53 PM EDT Send to a Friend
Raymond James analyst Sean McCutcheon reiterated an Outperform rating and $86.00 price target on Legend Biotech Corp. (NASDAQ: LEGN)The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login